Skip to main content
OpenTrials
Completed

NCT Number: NCT05037045

Effect of Gene Polymorphisms on GLP-1 Receptor Agonists Response in Patients With T2DM

1. This is an prospective study to evaluate the effect of gene polymorphisms on therapeutic responses to glucagon like peptide-1 receptor agonist (GLP-1 RA) in patients with T2DM. 2. T2DM patients and healthy subjects were recruited to identify genotypes and detect the level of T2DM susceptibility genes expression levels in the plasma of healthy participants and T2DM patients. 3. This is a retrospective cohort study of patients with T2DM who were treated with exenatide twice daily as a part of their diabetes care for at least 12 months.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Type 2 Diabetes Mellitus Diabetes Mellitus Diabetes Mellitus, Type 2 Endocrine System Diseases Glucose Metabolism Disorders Metabolic Diseases Nutritional and Metabolic Diseases

Age range

25 year–70 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Department of Endocrinology

Xuzhou, Jiangsu, China

About this study

Many guidelines recommend the preferential use of GLP-1 RA after single drug or multiple oral hypoglycemic drugs and basic insulin therapy for poor glycemic control. However, the clinical responsiveness to GLP-1 RA varies among patients with T2DM. It has been reported that genetic factors are the important reasons for individual variation in therapeutic response of antidiabetic drugs. At present, dozens of gene loci related to therapeutic response of antidiabetic drugs have been screened, which are of great clinical significance in guiding clinical individualized treatment, improving the efficacy and safety of drugs, and reducing the drug costs.

GLP-1 RA was injected subcutaneously at standard dose and frequency for consecutive 6 months. The patients were visited at moths 0, 3, and 6, and medical histories, physical examinations, and routine clinical laboratory tests were performed during these visits. The general anthropometric parameters considered for this study were height (m), weight (kg), and waist and hip circumferences (cm) at baseline, 3 months and 6months after exenatide treatment. After an overnight fast, venous blood samples were obtained both in the fasting state and 2 h later during a standard 75-g oral glucose tolerance test. Parameters were measured at baseline, the end of months 3 and 6 after administration of exenatide.

Peripheral blood was collected at follow-up and genomic DNA was extracted from peripheral blood leucocytes. We further explored the association of gene polymorphisms with the therapeutic effect of GLP-1 RA in patients with T2DM.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • a diagnosis of T2DM；
  • a body mass index (BMI) of 20-35 kg/m2；
  • an HbA1c of 7.0%-12%, an age of 25-70 years；
  • required data available at baseline, 3 months, and 6 months after GLP-1 RA therapy.

Exclusion criteria

  • Patients with serious diseases such as acute myocardial infarction, cerebral vascular accident, trauma, kidney or liver diseases, severe gastrointestinal dysfunction, and history of pancreatitis；
  • patients receiving GLP-1 analogues, weight loss drugs, glucocorticoids, drugs affecting gastrointestinal peristalsis in the past 3 months；
  • those with missing data at the time points of baseline, 3 months, and 6 months after GLP-1 RA therapy.

Treatment and study plan

GLP-1 receptor agonist

Drug

GLP-1 RA was injected subcutaneously at standard dose and frequency for consecutive 6 months in patients with T2DM

Other names: GLP-1 analogues

Primary outcomes

  1. Change from baseline HbA1c at 1 month

    Time frame: 1 month after GLP-1 RA treatment

    In order to observe the change from baseline HbA1c at 1 month after GLP-1 RA treatment

  2. Change from baseline FPG at 1 month

    Time frame: 1 month after GLP-1 RA treatment

    In order to observe the change from baseline FPG at 1 month after GLP-1 RA treatment

  3. Change from baseline PPG at 1 month

    Time frame: 1 month after GLP-1 RA treatment

    In order to observe the change from baseline PPG at 1 month after GLP-1 RA treatment

  4. Change from baseline serum lipids at 1 month

    Time frame: 1 month after GLP-1 RA treatment

    In order to observe the change from baseline serum lipids at 1 month after GLP-1 RA treatment

  5. Change from baseline HbA1c at 3 month

    Time frame: 3 month after GLP-1 RA treatment

    In order to observe the change from baseline HbA1c at 3 month after GLP-1 RA treatment

  6. Change from baseline FPG at 3 month

    Time frame: 3 month after GLP-1 RA treatment

    In order to observe the change from baseline FPG at 3 month after GLP-1 RA treatment

  7. Change from baseline PPG at 3 month

    Time frame: 3 month after GLP-1 RA treatment

    In order to observe the change from baseline PPG at 3 month after GLP-1 RA treatment

  8. Change from baseline serum lipids at 3 month

    Time frame: 3 month after GLP-1 RA treatment

    In order to observe the change from baseline serum lipids at 3 month after GLP-1 RA treatment

  9. Change from baseline HbA1c at 6 month

    Time frame: 6 month after GLP-1 RA treatment

    In order to observe the change from baseline HbA1c at 6 month after GLP-1 RA treatment

  10. Change from baseline FPG at 6 month

    Time frame: 6 month after GLP-1 RA treatment

    In order to observe the change from baseline FPG at 6 month after GLP-1 RA treatment

  11. Change from baseline PPG at 6 month

    Time frame: 6 month after GLP-1 RA treatment

    In order to observe the change from baseline PPG at 6 month after GLP-1 RA treatment

  12. Change from baseline serum lipids at 6 month

    Time frame: 6 month after GLP-1 RA treatment

    In order to observe the change from baseline serum lipids at 6 month after GLP-1 RA treatment

Secondary outcomes

  1. incidence and severity of possible adverse reaction within 1 month after GLP-1 RA treatment

    Time frame: 1 month after GLP-1 RA treatment

    To evaluate the incidence and severity of possible adverse reaction within 1 month after GLP-1 RA treatment, including gastrointestinal reaction and hypoglycemia

  2. incidence and severity of possible adverse reaction within 3 month after GLP-1 RA treatment

    Time frame: 3 month after GLP-1 RA treatment

    To evaluate the incidence and severity of possible adverse reaction within 3 month after GLP-1 RA treatment, including gastrointestinal reaction and hypoglycemia

  3. incidence and severity of possible adverse reaction within 6 month after GLP-1 RA treatment

    Time frame: 6 month after GLP-1 RA treatment

    To evaluate the incidence and severity of possible adverse reaction within 6 month after GLP-1 RA treatment, including gastrointestinal reaction and hypoglycemia

Sponsors and collaborators

Lead sponsor

The Affiliated Hospital of Xuzhou Medical University

Other

Registry information

Official study title

Department of Pharmacy, the Affiliated Hospital of Xuzhou Medical University

Important dates

Study start
2019
Primary completion
2023
Study completion
2024
First posted
Sep 8, 2021
Registry last updated
Nov 12, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.